Medicare is now offering $50 GLP-1 prescriptions. The US may never be the same.

Three ways GLP-1s are about to change America.

The latest breakthrough for GLP-1 drugs isn’t scientific. It’s financial.

As of July 1, Medicare is providing coverage of GLP-1 medications for weight loss for just a $50 co-pay, potentially enabling millions more Americans to get onto this much-hyped new class of drugs. Medicare’s GLP-1 Bridge Program, as it is called, is technically a one-year pilot project authorized by the Trump administration. Medicare previously limited GLP-1 coverage to people who have diabetes, heart disease, or obstructive sleep apnea.

Under the new program, Medicare enrollees will be eligible to receive one of three drugs — Foundayo (the new once-a-day tablet), Wegovy, or Zepbound — for weight loss specifically. Patients generally qualify if they have a body mass index of 35 or higher, or a BMI of 27 or higher with certain health conditions.

The new program could prove to be an inflection point for a class of drugs that has already generated so much excitement and interest. It is a story with enormous implications, not only for Americans’ health, but for the economy at large.

“We call [this drug] a physiological disruption akin to technological disruptions of our time like the smartphone. When the smartphone first came out, no one anticipated Uber or TikTok or Netflix streaming,” Alison Furman, partner and US consumer markets industry leader at PwC, said at Aspen Ideas: Health. “This is no different. You are going to see new brands, new products, new industries form around this ecosystem that this drug is already creating.”

The percentage of households with a GLP-1 user had already doubled from January 2025 to May 2026, per PwC. And that was before the launch of the Bridge program, which seems likely to act as an accelerant on several trends that are already underway.

A lot more Americans are about to start taking a GLP-1 drug

About 12 percent of Americans said in an August 2025 survey that they had taken a GLP-1 drug — equivalent to more than 40 million people. As of May 2026, one in five US households had at least one GLP-1 user, according to data from PwC — and those shares are probably as low as they will ever be.

Millions more are likely to join them with Medicare’s coverage........

© Vox